Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib and Tislelizumab as Adjuvant Therapy for High-Risk HCC
NCT05545124Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of donafenib, tislelizumab in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
donafenibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05545124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545124.